vimarsana.com

Latest Breaking News On - Jakob lindberg - Page 3 : vimarsana.com

Oncopeptides enters into a renewed loan facility agreement of up to €30 million with the European Investment Bank

/PRNewswire/ Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat.

United kingdomRolf gulliksenJakob lindbergEuropean unionGlobal head of corporate communicationsEuropean investment bankNasdaq stockholmEuropean economic areaGlobal headCorporate communicationsPeptide drug candidateMarketing authorizationMid capEuropean investment

Oncopeptides enters into a renewed loan facility agreement of up to €30 million with the European Investment Bank

/PRNewswire/ Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat.

United kingdomRolf gulliksenJakob lindbergEuropean unionGlobal head of corporate communicationsEuropean investment bankNasdaq stockholmEuropean economic areaGlobal headCorporate communicationsPeptide drug candidateMarketing authorizationMid capEuropean investmentOncopeptides ab

Oncopeptides enters into a renewed loan facility agreement of up to €30 million with the European Investment Bank

/PRNewswire/ Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat.

United kingdomRolf gulliksenJakob lindbergEuropean unionGlobal head of corporate communicationsEuropean investment bankNasdaq stockholmEuropean economic areaGlobal headCorporate communicationsPeptide drug candidateMarketing authorizationMid capEuropean investment

Oncopeptides publishes Q3 report 2022

/PRNewswire/ Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat.

United kingdomAnnika muskantorRolf gulliksenJakob lindbergSweden innovation agencyOncologic drugs advisory committeeEuropean unionEuropean commissionGlobal head of corporate communicationsNasdaq stockholmGeneral meetingDrugs advisory committeeInnovation agencyChief executive officer jakob lindbergChief commercial officer sofia heigisChief financial officer annika

Oncopeptides announces the market potential for Pepaxti in Europe

/PRNewswire/ Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat.

Jakob lindbergEuropean unionEuropean medicines agencyEuropean commissionGlobal head of corporate communicationsNasdaq stockholmMarketing authorizationEuropean economic areaCorporate communicationsPeptide drug candidateMid capOncopeptides ab

vimarsana © 2020. All Rights Reserved.